Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 18-70 years~* ischemic chest pain for \>30 min~* admitted to hospital \<24 h after the onset of chest pain~* electrocardiography showed ST segment elevation \>1 mm in two consecutive leads in the limb leads or \>2 mm in the precordial leads~* they could be enrolled in the study \<72 h after successful revascularization~Exclusion Criteria:~* cardiogenic shock (defined as systolic blood pressure \<90 mmHg requiring intravenous pressors or intra-aortic balloon counterpulsation)~* life-threatening arrhythmia~* impossible conditions for cardiac catheterization~* advanced renal or hepatic dysfunction~* history of previous coronary artery bypass graft~* history of hematologic disease~* history of malignancy~* major bleeding requiring blood transfusion~* stroke or transient ischemic attack in the previous 6 months~* structural abnormalities of the central nervous system (brain tumor, aneurysm, history of surgery)~* traumatic injury after myocardial infarction~* use of corticosteroids or antibiotics during the previous month~* major surgical procedure in the previous 3 months~* cardiopulmonary resuscitation for \>10 min within the previous 2 weeks~* positive skin test for penicillin~* positive result for viral markers (human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL) test)~* pregnancy, possible candidate for pregnancy or breastfeeding females~* drug abusers~* inappropriate patients to participate in the study according to the chief investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cell treatment group (Type: ACTIVE_COMPARATOR): None
- Control group (Type: PLACEBO_COMPARATOR): All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)

Based on this trial design, predict the completion outcome and termination type (if applicable).